Search

everythinglearnresearchcommunity

for

Search:↓

Naming a child after hair loss treatments like Propecia and Finasteride, with most users advising against it. The conversation includes humorous and critical responses, suggesting more conventional names.

A user's personal hair loss progress with treatments, including finasteride (1.25mg), minoxidil, needling, and Nizoral; and advice from other users on how to perform the needling correctly.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

The user is experiencing positive hair regrowth results after four months of using oral finasteride (1mg daily), oral minoxidil (5mg daily), Polaris NR02 shampoo, and ketoconazole 2% shampoo. They plan to continue the regimen and consider a hair transplant in the future, with no reported side effects from the current treatment.

The user started using EssenGen 6-Plus, containing 6% minoxidil and 0.05% finasteride, along with 1% Nizoral shampoo, and reported noticeable hair growth in 7 weeks. They experienced some chest tightness but are monitoring it, and they are satisfied with the progress despite using a silicone-containing shampoo.

People are eagerly awaiting the release of PP405, a new hair loss treatment. Some are using minoxidil and finasteride in the meantime, but there are concerns about scams and unverified products.

A user shared a 7-month hair loss treatment progress using finasteride 1.25 mg, oral minoxidil 2.5 mg, ketoconazole shampoo, and monthly micro-needling, noting denser hair and improved quality but no significant regrowth. They experienced mild testicular discomfort and heart palpitations, considering switching to topical minoxidil to avoid side effects.

The user is discussing hair regrowth after 7 months of using topical minoxidil and RU58841, with some microneedling. They are hesitant to switch to finasteride or dutasteride and are seeking input on whether there is new growth or just more miniaturization.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

The user started taking zinc for a deficiency and is discussing one month of progress. They are inquiring if the observed changes indicate hair regrowth.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

A user asked if taking a blood test 3 days after starting finasteride would affect the results for Estradiol, FSH, SHBG, Progesterone, and DHEA-S. The conversation is about the timing of blood tests after beginning finasteride treatment.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The user is experiencing hair regrowth after five months on a treatment regimen including Musely's bloom+ pill (Minoxidil and Dutasteride), Nizoral, and microneedling. They are optimistic about the results and have not experienced any side effects.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

The conversation discusses using cyproterone temporarily to reverse hair loss, followed by finasteride to maintain regrowth. Concerns about cyproterone's side effects, such as lowering testosterone and potential health risks, are raised, with alternatives like spironolactone suggested for androgen-related issues.

The conversation discusses a 33-year-old man's experience with hair regrowth after three months using topical finasteride, 5% minoxidil, saw palmetto, and scalp massages. Specific treatments for hair loss are being evaluated for their effectiveness.

A user's progress with hair loss treatments over the past two years, including finasteride, minoxodil and dermarolling. Replies included speculations about whether or not this was the result of a hair transplant. The user confirmed that it was just meds.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

The user has been using topical Minoxidil and Finasteride for 5 months and is questioning whether the new hair growth is genuine or just thin existing hairs. Another user suggests that comparison with before pictures is necessary to determine progress.

New hair loss treatments like Shiseido/Replicel and Histogen were discussed, with cautious optimism about their availability by 2018. Setipiprant, Replicel, and Bimatoprost were mentioned as potential treatments expected around 2016-2017.

The user shared progress pictures showing hair improvement after using 1mg oral finasteride and topical minoxidil daily for three months. They experienced initial side effects but reported no issues after five weeks, and the conversation includes discussions on the effectiveness and side effects of these treatments.

The user experienced hair regrowth using finasteride and minoxidil over 8 months, with noticeable improvements starting in June. They reported side effects like erectile dysfunction and flakes but continued treatment as the effects were not permanent.

Finasteride can cause sexual side effects in less than 2% of men, but these often disappear over time, even if the treatment continues. Some users report persistent side effects, while others experience no issues or only temporary ones.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A user experienced increased estradiol, nipple tenderness, and ED after taking finasteride. They are considering dose reduction to mitigate these effects.

The user has been taking oral minoxidil, dutasteride, and biotin for 3 months and noticed changes in hair texture, suggesting potential regrowth or stabilization. Baby hairs and increased hair density are seen as positive signs.